FDA approves Ferring’s Rebyota for recurrent Clostridioides difficile infection
The approval is based on the findings from a clinical programme including data from the late-stage PUNCH CD3…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
01 Dec 22
The approval is based on the findings from a clinical programme including data from the late-stage PUNCH CD3…
29 Nov 22
The clinical-stage company took an immunoproteomics approach to extract and identify naturally presented MHC Class I-restricted peptides on…
25 Nov 22
The MAA submission to the MHRA for NPC and ESCC indications is based on findings from the JUPITER-02…
24 Nov 22
The XeriJect formulation technology will be used for producing an ultra-concentrated, ready-to-use, subcutaneous injection of the ophthalmic drug
23 Nov 22
Libtayo is now indicated for the treatment of four cancer types in the European Union
21 Nov 22
The expanded authorisation in Canada was based on the findings of a phase 2 clinical trial held in…
18 Nov 22
The EC approval for Enjaymo was driven by the findings from the CADENZA and CARDINAL phase 3 clinical…
17 Nov 22
The FDA advisory committee voted nine to four in favour of XPHOZAH as monotherapy and ten to two…
16 Nov 22
Indivior will acquire Opiant at a price of $20 per share, for around $145m, in addition to $8…
16 Nov 22
The new Amazon Clinic will be accessible initially in 32 states and will offer virtual care for various…